Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

641 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.
Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL. Kaasenbrood L, et al. Among authors: van der graaf y. Circulation. 2016 Nov 8;134(19):1419-1429. doi: 10.1161/CIRCULATIONAHA.116.021314. Epub 2016 Sep 28. Circulation. 2016. PMID: 27682883 Free article.
High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect.
Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. Dorresteijn JA, et al. Among authors: van der graaf y. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14. Circulation. 2013. PMID: 23674398
Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
van de Woestijne AP, van der Graaf Y, Liem AH, Cramer MJ, Westerink J, Visseren FL; SMART Study Group. van de Woestijne AP, et al. Among authors: van der graaf y. J Am Coll Cardiol. 2013 Nov 12;62(20):1834-41. doi: 10.1016/j.jacc.2013.04.101. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23948286 Free article.
The relation between the presence of cardiovascular disease and vascular risk factors in offspring and the occurrence of new vascular events in their parents already at high vascular risk.
Weijmans M, van der Graaf Y, de Borst GJ, Asselbergs FW, Cramer MJ, Algra A, Visseren FL; SMART study group. Weijmans M, et al. Among authors: van der graaf y. Am Heart J. 2015 Oct;170(4):744-752.e2. doi: 10.1016/j.ahj.2015.06.023. Epub 2015 Jul 3. Am Heart J. 2015. PMID: 26386798
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL; CARDS, ALLHAT, and ASCOT Investigators. Kaasenbrood L, et al. Among authors: van der graaf y. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):213-21. doi: 10.1161/CIRCOUTCOMES.115.001980. Epub 2016 May 11. Circ Cardiovasc Qual Outcomes. 2016. PMID: 27174798 Free article. Clinical Trial.
The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease.
Bots SH, van der Graaf Y, Nathoe HM, de Borst GJ, Kappelle JL, Visseren FL, Westerink J; SMART Study Group. Bots SH, et al. Among authors: van der graaf y. Cardiovasc Diabetol. 2016 Jul 19;15(1):101. doi: 10.1186/s12933-016-0418-1. Cardiovasc Diabetol. 2016. PMID: 27431507 Free PMC article.
641 results